[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-335226-en":59,"doc-seo-335226-105":81},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":4},335226,7971461740886,"Theodore","https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer - The Phase II BALTIC Study","Phase II BALTIC study (NCT02937818) evaluated novel combination regimens for platinum-refractory or resistant extensive-stage small cell lung cancer (ES-SCLC) using a multiarm, signal-seeking design. Patients with ES-SCLC and progressive disease during or within 90 days after first-line platinum chemotherapy received durvalumab plus tremelimumab followed by durvalumab (arm A), adavosertib plus carboplatin (arm B), or ceralasertib plus olaparib (arm C). The primary endpoint was objective response rate. Confirmed ORRs were 7.3% (A), 0% (B), and 4.8% (C), with safety consistent with individual drugs.","Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study  \nNiels Reinmuth1,2, Oscar Juan-Vidal3, Dariusz Kowalski4, Maciej Bryl5, Anna Kryzhanivska6, David Vicente7, Zsolt Horvth8, Gabriella Glffy9, Eszter Csnky10, Zsolt Ppai Szkely11, Ihor Vynnychenko12, Jon Armstrong13, Tapashi Dalvi14, Mingchao Xie15, Sonia Iyer15, Yashaswi Shrestha14, Haiyi Jiang14, and Igor Bondarenko16  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: The phase II, multiarm, signal-searching BALTIC study (NCT02937818) assessed novel treatment combinations for platinumrefractory/resistant extensive-stage small cell lung cancer (ES-SCLC).\u003Cbr>Patients and Methods: Patients with ES-SCLC with progressive disease during or within 90 days of completing first-line platinum-based chemotherapy received one of three regimens: durvalumab plus tremelimumab followed by durvalumab monotherapy (arm A), adavosertib plus carboplatin (arm B), or ceralasertib plus olaparib (arm C) . The primary endpoint was the objective response rate. Prespecified exploratory biomarker analyses were conducted in arms A and C.\u003Cbr>Results: In arm A (n ¼ 41), arm B (n ¼ 10), and arm C (n ¼ 21), the confirmed objective response rates were 7.3%, 0%, and 4.8%, respectively. Safety profiles in all arms were consistent with those of the individual drugs. In arm A, patients with PD-L1 expression (tumor\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | cells or immune cells) ≥1% seemed to have a greater likelihood of achieving disease control with durvalumab plus tremelimumab than those with PD-L1 (tumor cells and immune cells) \u003C1%, and lower baseline ctDNA and reduction in the on-treatment ctDNA level were both associated with longer overall survival. Among patients treated with ceralasertib plus olaparib in arm C, specific immune responserelevant circulating chemokines and cytokines were identified as early biomarkers of survival and pharmacodynamic biomarkers.\u003Cbr>Conclusions: In BALTIC, all combination regimens demonstrated tolerable safety profiles, but antitumor activity was limited in refractory/resistant ES-SCLC. Among patients treated with durvalumab plus tremelimumab, an association of on-treatment reduction in ctDNA with longer overall survival suggests the potential use of ctDNA as a surrogate of treatment response, warranting further investigation. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nPlatinum-based chemotherapy was the primary treatment modality for patients with extensive-stage small cell lung cancer (ES-  \n1Department of Thoracic Oncology, Asklepios Lung Clinic Munich-Gauting, Gauting, Germany. 2German Center of Lung Research, LMU Munich, Munich, Germany. 3Department of Medical Oncology, La Fe University Hospital, Valencia, Spain. 4Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Cur","cbCaia8PMFQatFps","https://ap.wps.com/l/cbCaia8PMFQatFps","pdf",2864915,13,"English","en",105,"# Purpose\n# Patients and Methods\n# Results\n## Objective response and safety\n## Biomarker analyses and ctDNA findings\n# Conclusions\n# Introduction","[{\"question\":\"What did the Phase II BALTIC study evaluate in platinum-refractory ES-SCLC?\",\"answer\":\"It assessed novel treatment combinations for platinum-refractory/resistant extensive-stage small cell lung cancer using three multiarm regimens and objective response rate as the primary endpoint.\"},{\"question\":\"What treatment regimens were assigned to arms A, B, and C?\",\"answer\":\"Arm A received durvalumab plus tremelimumab followed by durvalumab alone; arm B received adavosertib plus carboplatin; arm C received ceralasertib plus olaparib.\"},{\"question\":\"How did ctDNA and PD-L1 relate to outcomes in the durvalumab-based arm?\",\"answer\":\"In arm A, higher PD-L1 expression (≥1%) appeared associated with greater likelihood of disease control, and lower baseline ctDNA and reduction in on-treatment ctDNA correlated with longer overall survival.\"}]","Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer - The Phase II BALTIC Study | PDF",1790010214,33,{"code":4,"msg":82,"data":83},"ok",{"site_id":75,"language":74,"slug":84,"title":65,"keywords":85,"description":66,"schema_data":86,"social_meta":140,"head_meta":142,"extra_data":144,"updated_unix":145},"novel-combinations-of-immunotherapies-or-dna-damage-repair-inhibitors-in-platinum-refractory-extensive-stage-small-cell-lung-cancer-the-phase-ii-baltic-study","",{"@graph":87,"@context":139},[88,102,122],{"@type":89,"itemListElement":90},"BreadcrumbList",[91,95,97,100],{"item":92,"name":93,"@type":94,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":96,"name":9,"@type":94,"position":14},"https://docshare.wps.com/document/",{"item":98,"name":40,"@type":94,"position":99},"https://docshare.wps.com/document/research-report/",3,{"item":101,"name":65,"@type":94,"position":19},"https://docshare.wps.com/document/novel-combinations-of-immunotherapies-or-dna-damage-repair-inhibitors-in-platinum-refractory-extensive-stage-small-cell-lung-cancer-the-phase-ii-baltic-study/335226/",{"url":101,"name":65,"@type":103,"image":104,"author":109,"headline":65,"publisher":111,"fileFormat":114,"inLanguage":74,"description":66,"dateModified":115,"datePublished":116,"encodingFormat":114,"isAccessibleForFree":117,"interactionStatistic":118},"DigitalDocument",{"url":105,"@type":106,"width":107,"height":108},"https://docshare.wps.com/thumbnails/novel-combinations-of-immunotherapies-or-dna-damage-repair-inhibitors-in-platinum-refractory-extensive-stage-small-cell-lung-cancer-the-phase-ii-baltic-study/335226.png","ImageObject",300,407,{"name":63,"@type":110},"Person",{"url":92,"name":112,"@type":113},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":119,"interactionType":120,"userInteractionCount":29},"InteractionCounter",{"@type":121},"ViewAction",{"@type":123,"mainEntity":124},"FAQPage",[125,131,135],{"name":126,"@type":127,"acceptedAnswer":128},"What did the Phase II BALTIC study evaluate in platinum-refractory ES-SCLC?","Question",{"text":129,"@type":130},"It assessed novel treatment combinations for platinum-refractory/resistant extensive-stage small cell lung cancer using three multiarm regimens and objective response rate as the primary endpoint.","Answer",{"name":132,"@type":127,"acceptedAnswer":133},"What treatment regimens were assigned to arms A, B, and C?",{"text":134,"@type":130},"Arm A received durvalumab plus tremelimumab followed by durvalumab alone; arm B received adavosertib plus carboplatin; arm C received ceralasertib plus olaparib.",{"name":136,"@type":127,"acceptedAnswer":137},"How did ctDNA and PD-L1 relate to outcomes in the durvalumab-based arm?",{"text":138,"@type":130},"In arm A, higher PD-L1 expression (≥1%) appeared associated with greater likelihood of disease control, and lower baseline ctDNA and reduction in on-treatment ctDNA correlated with longer overall survival.","https://schema.org",{"og:url":101,"og:type":141,"og:title":65,"og:site_name":112,"og:description":66},"article",{"robots":143,"canonical":101},"index,follow",{"doc_id":61,"site_id":75},1790855120]